Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 20/20 | 1.00 |
| ▸ | WDR77 | Q9BQA1 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29980737 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24364491 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24366422 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29980489 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24367170 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24364492 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24367242 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24363971 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24365449 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL30470875 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | PRMT5 3142/4885WDR77 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.